Perrigo Completes Sale of Dermacosmetics Business for €332.6 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy PRGO?
Source: PRnewswire
- Significant Transaction Value: Perrigo has completed the sale of its Dermacosmetics business to Karo Healthcare for a total consideration of up to €332.6 million, which includes €305.6 million in upfront cash and an additional €27 million contingent on sales milestones, reflecting the company's proactive asset disposal strategy.
- Enhanced Financial Flexibility: The net proceeds from this transaction are expected to primarily reduce debt, thereby enhancing the company's financial flexibility and improving its balance sheet to support sustainable growth in the future.
- Brand Impact: The brands sold include ACO, Biodermal, Emolium, and Iwostin, with the Dermacosmetics business generating approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income, highlighting the significance of this business in the company's overall strategy.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction marks an important milestone in the execution of the company's Three-S plan, which aims to stabilize, streamline, and strengthen the company by sharpening its focus on core categories and enhancing competitive advantages.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 11.840
Low
18.00
Averages
20.33
High
23.00
Current: 11.840
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perrigo Sells Dermacosmetics Business for €332.6 Million, Reducing Debt by €306 Million
- Transaction Overview: Perrigo has completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, including €305.6 million in upfront cash and €27 million contingent on sales milestones, marking a significant step in the company's strategic transformation.
- Enhanced Financial Flexibility: The transaction is expected to yield approximately €306 million in net proceeds, primarily aimed at debt reduction, thereby enhancing the company's financial flexibility and strengthening its balance sheet to support sustainable future growth.
- Market Performance: In 2025, Perrigo's Dermacosmetics business generated around €120 million in net sales, representing about 5% of the company's adjusted operating income, allowing Perrigo to focus more on its core business areas following the sale.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction is a crucial milestone in executing the Three-S plan (Stabilize, Streamline, Strengthen), aimed at enhancing competitive advantages and shareholder value through portfolio streamlining.
See More
Perrigo Completes Sale of Dermacosmetics Business for €332.6 Million
- Significant Transaction Value: Perrigo has completed the sale of its Dermacosmetics business to Karo Healthcare for a total consideration of up to €332.6 million, which includes €305.6 million in upfront cash and an additional €27 million contingent on sales milestones, reflecting the company's proactive asset disposal strategy.
- Enhanced Financial Flexibility: The net proceeds from this transaction are expected to primarily reduce debt, thereby enhancing the company's financial flexibility and improving its balance sheet to support sustainable growth in the future.
- Brand Impact: The brands sold include ACO, Biodermal, Emolium, and Iwostin, with the Dermacosmetics business generating approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income, highlighting the significance of this business in the company's overall strategy.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction marks an important milestone in the execution of the company's Three-S plan, which aims to stabilize, streamline, and strengthen the company by sharpening its focus on core categories and enhancing competitive advantages.
See More
Perrigo Declares $0.29 Quarterly Dividend Amid Market Challenges
- Dividend Declaration: Perrigo has declared a quarterly dividend of $0.29 per share, consistent with previous distributions, indicating the company's stability in the current market environment and likely appealing to income-seeking investors.
- Yield Performance: The forward yield of 10.08% not only reflects the company's commitment to shareholder returns but may also enhance investor interest in Perrigo's stock, particularly amid challenges in the soft OTC market.
- Shareholder Record Dates: The dividend will be payable on June 16, with a record date of May 29 and an ex-dividend date also set for May 29, ensuring shareholders receive timely returns and strengthening trust between the company and its investors.
- Future Outlook: Perrigo projects its core EPS to range between $2.25 and $2.55 by 2026, demonstrating confidence in future growth despite challenges in the OTC market, which may attract long-term investors' attention.
See More
Analysis of High-Yield Stocks in Healthcare Sector
- Perrigo's High Yield and Risks: With a forward dividend yield of 9.6%, Perrigo's stock has plummeted over 87.5% in the past decade, indicating the uncertainty behind its high yield, which investors must carefully assess as a potential value trap.
- Healthpeak's Restructuring Potential: As one of the largest healthcare REITs, Healthpeak Properties owns over 700 healthcare-related properties, currently offering a forward dividend yield of 7.1%, and its newly formed Janus Living could enhance its market value, attracting investors focused on capital growth.
- Dividend Cuts at Medical Properties Trust: Medical Properties Trust has a forward dividend yield of approximately 6.8%, but it has reduced its dividend twice due to the bankruptcy of major tenant Steward Health Care, highlighting its financial challenges.
- Financial Stability and Future Outlook: Despite facing tenant financial issues and over $2 billion in debt maturities, Medical Properties Trust's latest quarterly results show normalized funds from operations of $0.18 per share, suggesting it can sustain its current dividend for now.
See More
Perrigo to Release Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: Perrigo Company plans to announce its Q1 2026 financial results on May 6, 2026, and will host a conference call at 8:30 A.M. EST, reflecting its ongoing performance in the consumer health products sector.
- Conference Call Access: The earnings call will be available via live webcast and phone, allowing investors to participate by dialing 800-836-8184 or international 646-357-8785, ensuring broad investor engagement.
- Replay Availability: A taped replay of the call will be accessible starting at 12:00 P.M. on May 6 until midnight on May 13, with investors able to listen by calling 888-660-6345, enhancing the accessibility of information.
- Company Overview: Perrigo is a leading consumer health company focused on the OTC self-care market, leveraging strong brand and private label offerings to drive growth and meet consumer health needs.
See More
Perrigo Co. Speculated as Potential Takeover Target
- Takeover Speculation: Perrigo Co.'s stock surged by 7.5% amid rumors that Germany's Stada Arzneimittel AG may be interested in acquiring the company, reflecting market optimism about Perrigo's future and potentially attracting more investor attention.
- Market Performance: With a market cap of $1.46 billion and a short interest of 11.5%, the market's expectations for stock volatility could influence investor decisions and the company's financing capabilities.
- Dividend Appeal: Perrigo offers a double-digit dividend yield, attracting investors seeking stable returns, particularly in the current market environment, which may strengthen its shareholder base.
- Future Outlook: At the UBS Global Consumer and Retail Conference, Perrigo outlined a 2026 CORE EPS range of $2.25 to $2.55, indicating growth potential despite a soft OTC market, thereby boosting investor confidence.
See More
Perrigo Sells Dermacosmetics Business for €332.6 Million, Reducing Debt by €306 Million
- Transaction Overview: Perrigo has completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, including €305.6 million in upfront cash and €27 million contingent on sales milestones, marking a significant step in the company's strategic transformation.
- Enhanced Financial Flexibility: The transaction is expected to yield approximately €306 million in net proceeds, primarily aimed at debt reduction, thereby enhancing the company's financial flexibility and strengthening its balance sheet to support sustainable future growth.
- Market Performance: In 2025, Perrigo's Dermacosmetics business generated around €120 million in net sales, representing about 5% of the company's adjusted operating income, allowing Perrigo to focus more on its core business areas following the sale.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction is a crucial milestone in executing the Three-S plan (Stabilize, Streamline, Strengthen), aimed at enhancing competitive advantages and shareholder value through portfolio streamlining.
See More
Perrigo Completes Sale of Dermacosmetics Business for €332.6 Million
- Significant Transaction Value: Perrigo has completed the sale of its Dermacosmetics business to Karo Healthcare for a total consideration of up to €332.6 million, which includes €305.6 million in upfront cash and an additional €27 million contingent on sales milestones, reflecting the company's proactive asset disposal strategy.
- Enhanced Financial Flexibility: The net proceeds from this transaction are expected to primarily reduce debt, thereby enhancing the company's financial flexibility and improving its balance sheet to support sustainable growth in the future.
- Brand Impact: The brands sold include ACO, Biodermal, Emolium, and Iwostin, with the Dermacosmetics business generating approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income, highlighting the significance of this business in the company's overall strategy.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction marks an important milestone in the execution of the company's Three-S plan, which aims to stabilize, streamline, and strengthen the company by sharpening its focus on core categories and enhancing competitive advantages.
See More
Perrigo Declares $0.29 Quarterly Dividend Amid Market Challenges
- Dividend Declaration: Perrigo has declared a quarterly dividend of $0.29 per share, consistent with previous distributions, indicating the company's stability in the current market environment and likely appealing to income-seeking investors.
- Yield Performance: The forward yield of 10.08% not only reflects the company's commitment to shareholder returns but may also enhance investor interest in Perrigo's stock, particularly amid challenges in the soft OTC market.
- Shareholder Record Dates: The dividend will be payable on June 16, with a record date of May 29 and an ex-dividend date also set for May 29, ensuring shareholders receive timely returns and strengthening trust between the company and its investors.
- Future Outlook: Perrigo projects its core EPS to range between $2.25 and $2.55 by 2026, demonstrating confidence in future growth despite challenges in the OTC market, which may attract long-term investors' attention.
See More
Analysis of High-Yield Stocks in Healthcare Sector
- Perrigo's High Yield and Risks: With a forward dividend yield of 9.6%, Perrigo's stock has plummeted over 87.5% in the past decade, indicating the uncertainty behind its high yield, which investors must carefully assess as a potential value trap.
- Healthpeak's Restructuring Potential: As one of the largest healthcare REITs, Healthpeak Properties owns over 700 healthcare-related properties, currently offering a forward dividend yield of 7.1%, and its newly formed Janus Living could enhance its market value, attracting investors focused on capital growth.
- Dividend Cuts at Medical Properties Trust: Medical Properties Trust has a forward dividend yield of approximately 6.8%, but it has reduced its dividend twice due to the bankruptcy of major tenant Steward Health Care, highlighting its financial challenges.
- Financial Stability and Future Outlook: Despite facing tenant financial issues and over $2 billion in debt maturities, Medical Properties Trust's latest quarterly results show normalized funds from operations of $0.18 per share, suggesting it can sustain its current dividend for now.
See More
Perrigo to Release Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: Perrigo Company plans to announce its Q1 2026 financial results on May 6, 2026, and will host a conference call at 8:30 A.M. EST, reflecting its ongoing performance in the consumer health products sector.
- Conference Call Access: The earnings call will be available via live webcast and phone, allowing investors to participate by dialing 800-836-8184 or international 646-357-8785, ensuring broad investor engagement.
- Replay Availability: A taped replay of the call will be accessible starting at 12:00 P.M. on May 6 until midnight on May 13, with investors able to listen by calling 888-660-6345, enhancing the accessibility of information.
- Company Overview: Perrigo is a leading consumer health company focused on the OTC self-care market, leveraging strong brand and private label offerings to drive growth and meet consumer health needs.
See More
Perrigo Co. Speculated as Potential Takeover Target
- Takeover Speculation: Perrigo Co.'s stock surged by 7.5% amid rumors that Germany's Stada Arzneimittel AG may be interested in acquiring the company, reflecting market optimism about Perrigo's future and potentially attracting more investor attention.
- Market Performance: With a market cap of $1.46 billion and a short interest of 11.5%, the market's expectations for stock volatility could influence investor decisions and the company's financing capabilities.
- Dividend Appeal: Perrigo offers a double-digit dividend yield, attracting investors seeking stable returns, particularly in the current market environment, which may strengthen its shareholder base.
- Future Outlook: At the UBS Global Consumer and Retail Conference, Perrigo outlined a 2026 CORE EPS range of $2.25 to $2.55, indicating growth potential despite a soft OTC market, thereby boosting investor confidence.
See More
